Consenso de expertos en la asistencia multidisciplinaria y el abordaje integral de la insuficiencia cardiaca. Desde el alta hospitalaria hasta la continuidad asistencial con primaria / Expert consensus on multidisciplinary management and integrated approaches in heart failure. Continuity of care from hospital discharge to primary care

La insuficiencia cardiaca es una enfermedad que precisa un tratamiento multidisciplinario, dadas la diversidad de causas y entornos clínicos implicados que las tratan y las diferentes estrategias terapéuticas que precisan la participación indispensable de diversas disciplinas. La presencia en los servicios de cardiología de unidades de insuficiencia cardiaca centradas en el tratamiento de los pacientes con esta afección y unidades de rehabilitación cardiaca que, entre sus indicaciones para la reducción de la morbimortalidad, también están implicadas en la atención de esos mismos pacientes puede causar dificultades de coordinación y pérdida de una atención integral centrada en el paciente. Por estos motivos, en el presente documento se plantea una estrategia de coordinación entre las diferentes unidades implicadas en el tratamiento de los pacientes dentro de los servicios de cardiología y la continuidad asistencial con atención primaria, tanto tras haber conseguido la estabilidad como la interrelación para una coordinación posterior más efectiva

Heart failure is a condition that requires a multidisciplinary approach to treatment because of the wide range of causes and clinical contexts that may be involved and because the diverse treatment strategies used necessitate the participation of multiple disciplines. In cardiology departments, the presence of both heart failure units that focus on the treatment of affected patients and cardiac rehabilitation units that, as well as targeting reductions in morbidity and mortality, are also involved in caring for the same patients can create difficulties for coordination and can result in the loss of comprehensive patient-centered care. For these reasons, this paper presents a strategy for coordinating the different units involved in patient management in cardiology departments and for ensuring continuity of care in primary care, both immediately after achieving stabilization and subsequently, when these interactions are important for effective coordination

Diferencias en el pronóstico de la insuficiencia cardiaca con función sistólica conservada o deprimida en pacientes mayores de 70 años que toman bloqueadores beta / Differences in outcome of heart failure with preserved or depressed systolic function in patients older than 70 years who receive beta blockers

Introducción y objetivos. La mayoría de los trabajos han puesto de manifiesto que el pronóstico de la insuficiencia cardiaca con función sistólica conservada es tan malo como el de la insuficiencia cardiaca con función sistólica deprimida, aunque estos resultados pueden estar sesgados debido a que estos dos tipos de insuficiencia cardiaca tienen características distintas (edad, comorbilidades, tratamiento) que pueden influir en el pronóstico. Nuestro objetivo es evaluar si la morbimortalidad a corto plazo es distinta en estos dos subgrupos de insuficiencia cardiaca, con pacientes homogéneos en cuanto a edad, comorbilidad y tratamiento recibido. Métodos. Analizamos dos grupos de pacientes mayores de 70 años y que pudieran recibir bloqueadores beta, dados de alta consecutivamente tras un ingreso por insuficiencia cardiaca en 53 hospitales españoles (función sistólica deprimida, 245; función sistólica conservada, 374), y se comparó la morbimortalidad cardiovascular a los 3 meses del alta. Resultados. Las medias de edad fueron similares (77,5±4,8 frente a 78,2±5,5 años). La fracción de eyección ventricular izquierda fue de 56,2±8,1% frente a 33±6,9% (p<0,001). La incidencia del evento combinado (muerte, ingreso por insuficiencia cardiaca, síndrome coronario agudo o ictus) a los 3 meses del alta fue menor en los pacientes con insuficiencia cardiaca y función sistólica conservada (el 13,4 frente al 20,6%; p=0,026). Tener la función sistólica deprimida fue predictor independiente de mayor incidencia de eventos (odds ratio=1,732; p=0,048). Conclusiones. En pacientes de edad similar que reciben el mismo tratamiento, el pronóstico a corto plazo es mejor en los pacientes con insuficiencia cardiaca y función sistólica conservada que en aquellos con función sistólica deprimida (AU)

Introduction and objectives. Most studies have shown that prognosis of heart failure with preserved systolic function is as poor as that of heart failure with depressed systolic function, although these results may be biased by the fact that these types of heart failure have different characteristics (age, comorbidity, treatment), which can influence prognosis. Our aim was to determine whether short-term morbidity and mortality differed in these 2 subgroups of heart failure patients when they were comparable in terms of age, associated comorbidity, and therapy. Methods. We analyzed 2 groups of patients aged >70 years who were candidates to receive beta blockers (preserved systolic function, 245; depressed systolic function, 374), consecutively discharged from 53 participating Spanish hospitals with a diagnosis of heart failure, and compared cardiovascular morbidity and mortality 3 months after discharge. Results. Mean age was similar (77.5±4.8 vs 78.2±5.5 years). Left ventricular ejection fraction was 56.2%±8.1% vs 33%±6.9% (P<.001). The combined event rate (death, hospitalization for heart failure, acute coronary syndrome, or stroke) at 3 months after discharge was lower in patients with heart failure and preserved systolic function (13.4% vs 20.6%; P=.026). Depressed systolic function was an independent predictor of greater incidence of events (odds ratio=1.732; P=.048). Conclusions. In patients of similar age and receiving similar treatment, short-term prognosis is better in patients with heart failure and preserved systolic function than in those with depressed systolic function (AU)

Differences in outcome of heart failure with preserved or depressed systolic function in patients older than 70 years who receive beta blockers.

INTRODUCTION AND OBJECTIVES: Most studies have shown that prognosis of heart failure with preserved systolic function is as poor as that of heart failure with depressed systolic function, although these results may be biased by the fact that these types of heart failure have different characteristics (age, comorbidity, treatment), which can influence prognosis. Our aim was to determine whether short-term morbidity and mortality differed in these 2 subgroups of heart failure patients when they were comparable in terms of age, associated comorbidity, and therapy. METHODS: We analyzed 2 groups of patients aged >70 years who were candidates to receive beta blockers (preserved systolic function, 245; depressed systolic function, 374), consecutively discharged from 53 participating Spanish hospitals with a diagnosis of heart failure, and compared cardiovascular morbidity and mortality 3 months after discharge. RESULTS: Mean age was similar (77.5±4.8 vs 78.2±5.5 years). Left ventricular ejection fraction was 56.2%±8.1% vs 33%±6.9% (P<.001). The combined event rate (death, hospitalization for heart failure, acute coronary syndrome, or stroke) at 3 months after discharge was lower in patients with heart failure and preserved systolic function (13.4% vs 20.6%; P=.026). Depressed systolic function was an independent predictor of greater incidence of events (odds ratio=1.732; P=.048). CONCLUSIONS: In patients of similar age and receiving similar treatment, short-term prognosis is better in patients with heart failure and preserved systolic function than in those with depressed systolic function.

Effect of a training program for primary care physicians on the optimization of beta-blocker treatment in elderly patients with heart failure.

INTRODUCTION AND OBJECTIVES: Underuse of betablockers may contribute to elevated mortality in chronic heart failure. The aim of this study was to determine whether a specific interventional training program for primary care physicians would help optimize the use of beta-blockers in elderly chronic heart failure patients. METHODS: This randomized comparative study included 627 patients aged 70 years or more who were discharged consecutively from 53 Spanish hospitals with a principal diagnosis of chronic heart failure. In total, 292 health-care centers in the catchment areas of these hospitals were randomly assigned to two groups: one group of 146 centers carried out an interventional training program on beta-blocker use for primary care physicians belonging to the centers assigned to training, and 146 centers served as a control group. The main outcome variable was the percentage of patients who were receiving a beta-blocker at the maximum or maximum tolerated dose 3 months after hospital discharge. RESULTS: The patients' mean age was 78+/-5 years and 42% were women. There was no difference between the groups in demographic characteristics, clinical care, or treatment at discharge. The percentage of patients who received beta-blockers at the maximum tolerated dose 3 months after discharge was greater in the training group (49% vs. 38%; P=.014). Being treated in the training group was an independent predictor of receiving a beta-blocker at the MTD (odds ratio=2.46; 95% confidence interval, 1.29-4.69; P< .001). CONCLUSIONS: Implementation of an interventional training program on beta-blocker treatment for primary care physicians improved the use of these medications in elderly chronic heart failure patients.

Efecto de un programa de formación en atención primaria sobre la optimización del tratamiento con bloqueadores beta en pacientes ancianos con insuficiencia cardiaca / Effect of a training program for primary care physicians on the optimization of beta-blocker treatment in elderly patients with heart failure

Introducción y objetivos. La infrautilización de bloqueadores beta puede influir en la elevada mortalidad de la insuficiencia cardiaca. El objetivo de nuestro estudio es evaluar si un programa específico de intervención sobre médicos de atención primaria permite optimizar el uso de bloqueadores beta en pacientes ancianos con insuficiencia cardiaca. Métodos. Se diseñó un estudio aleatorizado y comparativo en el que se incluyó a 627 pacientes de 70 o más años, dados de alta de forma consecutiva con el diagnóstico principal de insuficiencia cardiaca en 53 hospitales españoles. Se realizó una asignación aleatoria de los 292 centros de salud de las áreas de esos hospitales a dos grupos (formación, 146 centros, y control, 146 centros), para impartir un programa de intervención y formación sobre bloqueadores beta a los médicos pertenecientes a los centros del grupo formación. La variable principal fue el porcentaje de pacientes que recibían la dosis máxima o máxima tolerada de bloqueadores beta a los 3 meses del alta. Resultados. La edad de los pacientes era de 78 ± 5 años; el 42% eran mujeres. No hubo diferencias entre ambos grupos en sus características demográficas, clínicas o en el tratamiento al alta. El porcentaje de pacientes que recibían la dosis máxima tolerada de bloqueadores beta a los 3 meses del alta fue mayor en el grupo formación (el 49 frente al 38%; p = 0,014); pertenecer al grupo formación fue predictor independiente de recibir la dosis máxima tolerada de bloqueadores beta (odds ratio = 2,46; intervalo de confianza del 95%, 1,29-4,69; p < 0,001). Conclusiones. Un programa de formación sobre bloqueadores beta en atención primaria mejora su uso en pacientes ancianos con insuficiencia cardiaca (AU)

Introduction and objectives. Underuse of betablockers may contribute to elevated mortality in chronic heart failure. The aim of this study was to determine whether a specific interventional training program for primary care physicians would help optimize the use of beta-blockers in elderly chronic heart failure patients. Methods. This randomized comparative study included 627 patients aged 70 years or more who were discharged consecutively from 53 Spanish hospitals with a principal diagnosis of chronic heart failure. In total, 292 health-care centers in the catchment areas of these hospitals were randomly assigned to two groups: one group of 146 centers carried out an interventional training program on beta-blocker use for primary care physicians belonging to the centers assigned to training, and 146 centers served as a control group. The main outcome variable was the percentage of patients who were receiving a beta-blocker at the maximum or maximum tolerated dose 3 months after hospital discharge. Results. The patients’ mean age was 78±5 years and 42% were women. There was no difference between the groups in demographic characteristics, clinical care, or treatment at discharge. The percentage of patients who received beta-blockers at the maximum tolerated dose 3 months after discharge was greater in the training group (49% vs. 38%; P=.014). Being treated in the training group was an independent predictor of receiving a beta-blocker at the MTD (odds ratio=2.46; 95% confidence interval, 1.29-4.69; P < .001). Conclusions. Implementation of an interventional training program on beta-blocker treatment for primary care physicians improved the use of these medications in elderly chronic heart failure patients (AU)

[Current status of heart transplantation in Spain]. / Situación actual del trasplante cardiaco en España.

Both the prevalence and incidence of heart failure are high in developed countries. The number of patients suffering from the condition is continuing to grow as life-expectancy increases and, consequently, the population ages. In Spain, the number of deaths due to heart failure is similar to that due to cancer. Various treatments for heart failure, including specific drugs, implantable devices (i.e. cardioverters and defibrillators) and temporary or permanent ventricular assist devices, have been shown to improve survival and are now used regularly. Nevertheless, some patients with heart failure, though small in number, will benefit from heart transplantation. The procedure clearly improves quality of life and prolongs survival for many years. However, heart transplantation is not a routine procedure. It can result in a variety of problems, most of which must be tackled using a multidisciplinary approach. The aim of this update was to provide a broad overview of current practices employed by heart transplantation teams in Spain.

Situación actual del trasplante cardiaco en España / Current status of heart transplantation in Spain

La insuficiencia cardiaca presenta una incidencia y una prevalencia elevadas en los países desarrollados. El número de pacientes que la padece es cada vez mayor debido al progresivo incremento de la esperanza de vida y, por lo tanto, al envejecimiento de la población. En España, la insuficiencia cardiaca produce un número de fallecimientos similar al de las neoplasias. Los diversos tratamientos utilizados para la insuficiencia cardiaca, como determinados fármacos, dispositivos implantables (resincronizadores y desfibriladores) y asistencias ventriculares temporales y definitivas, han demostrado mejorar la supervivencia de estos pacientes y se emplean de forma habitual. No obstante, hay un número, más bien pequeño, de pacientes con insuficiencia cardiaca que pueden beneficiarse de un trasplante cardiaco. Este procedimiento mejora ostensiblemente la calidad de vida y prolonga la supervivencia durante muchos años. Sin embargo, el trasplante cardiaco no es un procedimiento inocuo y puede producir múltiples y variados problemas que precisan, en la mayoría de los casos, de un enfoque multidisciplinario para su control. En este artículo de puesta al día se pretende exponer de forma general los conceptos actuales utilizados en España por los equipos de trasplante cardiaco (AU)

Both the prevalence and incidence of heart failure are high in developed countries. The number of patients suffering from the condition is continuing to grow as life expectancy increases and, consequently, the population ages. In Spain, the number of deaths due to heart failure is similar to that due to cancer. Various treatments for heart failure, including specific drugs, implantable devices (i.e.cardioverters and defibrillators) and temporary or permanent ventricular assist devices, have been shown to improve survival and are now used regularly. Nevertheless, some patients with heart failure, though small in number, will benefit from heart transplantation. The procedure clearly improves quality of life and prolongs survival for many years. However, heart transplantation is not a routine procedure. It can result in a variety of problems, most of which must be tackled using a multidisciplinary approach. The aim of this update was to provide a broad overview of current practices employed by heart transplantation teams in Spain (AU)

Heart transplantation in a patient with systemic mastocytosis.

Systemic mastocytosis is a hematologic disorder characterized by mast-cell proliferation and organ infiltration. A variety of stimuli and drugs can cause severe anaphylaxis in these patients. We report the case of a female patient diagnosed with systemic mastocytosis and advanced dilated cardiomyopathy in whom a heart transplant was successfully performed.

[Native valve Aspergillus fumigatus endocarditis with blood culture positive and negative for galactomannan antigen. Case report and literature review]. / Endocarditis por Aspergillus fumigatus en válvula nativa con hemocultivo positivo y galactomanano negativo. Descripción de un caso y revisión de la literatura.

Native valve endocarditis caused by Aspergillus spp. is an uncommon disease with a high mortality rate. Generally, Aspergillus is isolated from affected valve in post-mortem or biopsy specimens. However, its isolation from blood cultures is exceedingly rare. We report a case of fungal endocarditis in a native mitral valve with the isolation of Aspergillus fumigatus both in valve vegetation and in blood culture bottles. The patient underwent valve replacement and antifungal treatment with voriconazole and caspofungin, but he died on post-operative day 45 with disseminated aspergillosis confirmed by necropsy. Paradoxically, galactomannan antigen detection in serum was negative. This is the third case of Aspergillus endocarditis with positive blood culture reported in the literature.

Endocarditis por Aspergillus fumigatus en válvula nativa con hemocultivo positivo y galactomanano negativo. Descripción de un caso y revisión de la literatura / Native valve Aspergillus fumigatus endocarditis with blood culture positive and negative for galactomannan antigen. Case report and literature review

La endocarditis infecciosa causada por Aspergillus es infrecuente y sepresenta en pacientes con cirugía cardiaca previa o en inmunodeficientes.Por lo general, el aislamiento del moho se realiza post-mortem, si bien elcultivo de la válvula o, en muy pocos casos, el hemocultivo permiten suaislamiento. Describimos un caso de endocarditis infecciosa por Aspergillusfumigatus sobre válvula nativa mitral, con aislamiento de Aspergillus en lavegetación valvular y en el hemocultivo. A pesar del recambio valvular y derecibir una terapia combinada con voriconazol y caspofungina, el pacientefalleció con aspergilosis diseminada confirmada en la necropsia. El presentesería el tercer caso descrito de endocarditis infecciosa por Aspergillus conhemocultivo positivo. Paradójicamente, la determinación del antígeno degalactomanano fue negativa(AU)

Native valve endocarditis caused by Aspergillus spp. is an uncommon diseasewith a high mortality rate. Generally, Aspergillus is isolated from affected valvein post-mortem or biopsy specimens. However, its isolation from bloodcultures is exceedingly rare. We report a case of fungal endocarditis in anative mitral valve with the isolation of Aspergillus fumigatus both in valvevegetation and in blood culture bottles. The patient underwent valvereplacement and antifungal treatment with voriconazole and caspofungin, buthe died on post-operative day 45 with disseminated aspergillosis confirmed bynecropsy. Paradoxically, galactomannan antigen detection in serum wasnegative. This is the third case of Aspergillus endocarditis with positive bloodculture reported in the literature(AU)

Documento de consenso GESIDA/GESITRA-SEIMC, SPNS y ONT sobre trasplante de órgano sólido en pacientes infectados por el VIH en España (marzo 2005) / Consensus document from GESIDA/GESITRA-SIMC, SPNS and ONT on solid organ transplantation in patients with HIV infection in Spain (March 2005)

El trasplante de órgano sólido puede ser la única alternativa terapéutica en ciertos pacientes infectados por el virus de la inmunodeficiencia humana (VIH). La experiencia acumulada en América del Norte y Europa en los últimos 5 años indica que la supervivencia a los 3 años del trasplante de órgano sólido es similar a la de los pacientes no infectados por el VIH. Los criterios consensuados para seleccionar a los pacientes infectados por el VIH con indicación de trasplante son: no haber tenido infecciones oportunistas (a excepción de la tuberculosis, candidiasis esofágica o neumonía por Pneumocystis jiroveci ­antes carinii­), tener una cifra de linfocitos CD4 > 200 cél./μl (100 cél./μl en el caso del trasplante hepático) y una carga viral del VIH indetectable o suprimible con tratamiento antirretroviral. También se exige una abstinencia a la heroína y cocaína de 2 años de duración, pudiendo estar el paciente en programa de metadona. Los principales problemas del período postrasplante son las interacciones farmacocinéticas y farmacodinámicas entre los antirretrovirales y los inmunosupresores, el rechazo y la posibilidad de que la recidiva de la infección por el virus de la hepatitis C (VHC), que es una de las principales causas de mortalidad postrasplante hepático, siga una evolución peor. La experiencia del tratamiento con interferón pegilado y ribavirina es escasa en esta población hasta el momento actual (AU)

Solid organ transplantation may be the only therapeutic option for some human inmunodeficience virus (HIV)-infected patients. Experience in North America and Europe over the last five years has shown that three-year survival of these patients following organ transplantation is similar to that of HIV-negative patients. The consensus criteria for the selection of HIV patients for transplantation include the following: no opportunistic infections (except tuberculosis, esophageal candidiasis or Pneumocystis jiroveci ­ previously carinii ­ pneumonia), CD4 lymphocyte count above 200 cells/μl (100 cells/μl in the case of liver transplantation) and HIV viral load that is undetectable or suppressible with antiretroviral therapy. Also required is a two-year abstinence from heroin and cocaine, although the patient may be in a methadone program. The main problems in the post-transplantation period in these patients are pharmacokinetic and pharmacodynamic interactions between antiretorivirals and immunosuppressors, rejection, and the fact that the risk of relapsed HCV infection is exacerbated, and this is one of the main causes of post-liver transplantation (..) (AU)

[GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March, 2005)]. / Documento de consenso GESIDA/GESITRA-SEIMC, SPNS y ONT sobre trasplante de órgano sólido en pacientes infectados por el VIH en España (marzo 2005).

Solid organ transplant may be the only therapeutic alternative in some HIV-infected patients. Experience in North America and Europe during the last five years shows that survival at three years after an organ transplant is similar to that observed in HIV-negative patients. The criteria agreed upon to select HIV patients for transplant are: no opportunistic infections (except tuberculosis, oesophageal candidiasis or P. jiroveci -previously carinii- pneumonia), CD4 lymphocyte count above 200 cells/.L (100 cells/.L in the case of liver transplant) and an HIV viral load which is undetectable or suppressible with antiretroviral therapy. Another criterion is a two-year abstinence from heroin and cocaine, although the patient may be in a methadone programme. The main problems in the post-transplant period are pharmacokinetic and pharmacodynamic interactions between antiretorivirals and immunosuppressors, rejection and the management of relapse of HCV infection, which is one of the main causes of post-liver transplant mortality. Up to now, experience with pegylated interferon and ribavirin is scarce in this population. The English version of the manuscript is available at http://www.gesidaseimc.com.

Long-term results of cardiac transplantation.

Heart transplantation is a successful therapeutic option for patients with end-stage heart cardiomyopathy. From April 1991 to December 2000, 345 patients underwent heart transplantation at the Juan Canalejo Hospital. The mean age of recipients was 54.5 +/- 11.4 years; 286 (83%) were male patients. Idiopathic (52.2%) and ischemic (34.9%) end-stage cardiomyopathy were the main causes leading to transplantation. Ninety-four patients had undergone a previous heart operation. The mean left ventricular ejection fraction was 22.8 +/- 11.4. Forty patients (11.5%) were transplanted in urgent (status I) condition. The mean time spent on the waiting list was 35.9 days. In-hospital mortality was 10.6% and 24% for transplantations performed on an elective and urgent basis, respectively. Operative (30-day), one-year and six-year survival was 87.2%, 81.3% and 64%, respectively. In terms of actuarial survival, there were no significant differences with regard to the recipient's age, sex, previous cardiac surgery, and the etiology of the end-stage cardiomyopathy. The six-year actuarial survival for recipients receiving hearts from female donors was 59% compared with 72% for male donors (p = 0.05). There has been a low incidence of rejection, as well as cardiac graft vasculopathy. Actuarial survival at six years was 66% for patients transplantated on an elective basis compared with 57% for patients transplanted on an urgent basis (p = 0.04). The aim of the study was to evaluate long-term results for patients who underwent orthotopic heart transplantation. In our experience, status I is associated with a higher mortality.

[Familial dilated cardiomyopathy in patients transplanted for idiopathic dilated cardiomyopathy]. / Miocardiopatía dilatada familiar en pacientes trasplantados por miocardiopatía dilatada idiopática.

OBJECTIVE: To evaluate the prevalence, clinical features, and pattern of inheritance of familial dilated cardiomyopathy (DCM) in heart transplant patients. PATIENTS AND METHOD: Patients with idiopathic DCM who had undergone heart transplantation were invited to participate. Patients with alcohol abuse were excluded. A clinical evaluation, 12-lead ECG, echocardiogram, blood tests, and DNA extraction were performed in patients and relatives. Familial DCM was defined as the presence of at least one relative with idiopathic DCM. Possible familial DCM was considered when at least one relative had left ventricular enlargement (LVE) (> 112% predicted LVEDD). RESULTS: One hundred and ninety-nine relatives of 43 families were studied. DCM was familial in 11 probands (25.6%) and possibly familial in 11 (25.6%). Fifteen relatives had DCM (7.5%), 26 (13.1%) LVE, and 5 (2.5%) hypertrophic cardiomyopathy. The pattern of inheritance was autosomal dominant in most families. Five probands (3 with familial DCM) had antecedents of consanguinity and possible recessive inheritance. Six probands (14%, 1 with familial DCM) had relatives with conduction system defects. Creatine kinase was moderately increased in 9 relatives (4.5%), 3 of them with LVE. Fifteen patients had at least moderate alcohol intake. Three of them had familial DCM (relatives without alcohol abuse) and 6 had possible familial DCM. CONCLUSIONS: The prevalence of familial DCM is high in patients who undergo heart transplant. Left ventricular enlargement, conduction system abnormalities, and elevated creatine kinase may be early markers of familial disease. Hypertrophic cardiomyopathy is present in some relatives of patients with idiopathic DCM. Familial DCM is present in patients with a previous diagnosis of alcoholic DCM.

Miocardiopatía dilatada familiar en pacientes trasplantados por miocardiopatía dilatada idiopática / Familial dilated cardiomyopathy in patients transplanted for idiopathic dilated cardiomyopathy

Objetivo. Estudiar la prevalencia de miocardiopatía dilatada (MCD) familiar en pacientes trasplantados, los patrones de herencia y características de la enfermedad en las familias identificadas. Pacientes y método. Los pacientes trasplantados por MCD idiopática fueron invitados a participar en el estudio: evaluación clínica, electrocardiograma, ecocardiograma y análisis de sangre en pacientes y familiares. Se define como MCD familiar la presencia de al menos un familiar con MCD idiopática y posible MCD familiar cuando algún familiar tiene dilatación ventricular izquierda (diámetro telediastólico > 112 por ciento del previsto) con función sistólica normal. Resultados. Participaron 199 familiares de 43 familias. Se diagnosticó MCD familiar en 11 familias (25,6 por ciento) y posible MCD familiar en 11 (25,6 por ciento). Quince familiares tenían MCD (7,5 por ciento), 26 (13,1 por ciento) dilatación ventricular izquierda, y cinco (2,5 por ciento) miocardiopatía hipertrófica. El patrón de herencia fue autosómico dominante en la mayor parte de las familias. En cinco existía consanguinidad y posible herencia autosómica recesiva. Seis casos tenían familiares con trastornos de conducción. Se registraron cifras de creatincinasa elevadas en 9 familiares (4,5 por ciento), tres con dilatación ventricular izquierda. Quince pacientes referían consumo de alcohol al menos moderado. Tres de ellos tenían MCD familiar y seis posible MCD familiar. Conclusiones. a) La prevalencia de MCD familiar es alta en pacientes sometidos a trasplante; b) la dilatación ventricular izquierda, anomalías del sistema de conducción y elevaciones de la creatincinasa pueden ser marcadores precoces de enfermedad familiar; c) algunos pacientes con MCD idiopática tienen familiares con miocardiopatía hipertrófica, y d) puede haber MCD familiar en pacientes con MCD asociada a consumo de alcohol (AU)

Guías de práctica clínica de la Sociedad Española de Cardiología en pruebas de esfuerzo / Guidelines of the Spanish Society of Cardiology for clinical practice in exercise testing

La mayor parte de las pruebas de esfuerzo se realizan a pacientes adultos con cardiopatía isquémica en estudio o ya conocida. En los últimos años se ha producido la incorporación de las técnicas de imagen en este campo, mejorando así la información aportada por la prueba de esfuerzo convencional. Pero cada vez existen más situaciones que escapan a esta norma general, tanto en sujetos sanos (asintomáticos, atletas, discapacitados, etc.) como en pacientes con cardiopatías diferentes de la isquémica (insuficiencia cardíaca congestiva avanzada, hipertensión, trastornos del ritmo, cardiopatías congénitas etc.). Todos estos aspectos justifican un documento de consenso en España, necesariamente multidisciplinario. Este documento revisa en profundidad la metodología de las pruebas de esfuerzo convencionales, sin olvidar las realizadas con determinación de consumo de oxígeno. El papel de esta exploración en el manejo de la cardiopatía isquémica, así como las aplicaciones de las técnicas de imagen al campo de estrés, ocupan un lugar fundamental en esta revisión. Por último, se analiza la utilidad de las pruebas de esfuerzo en diversas cardiopatías no isquémicas y en diferentes poblaciones de sujetos sanos (AU)